Qiming Venture Partners Wins Six Awards on TMTpost 2025 Annual Pioneer List
China's venture capital market has entered a recovery channel, buoyed by the flood of AI.
Recently, TMTpost 2025 Annual Pioneer Rankings were officially released, with Qiming Venture Partners winning six major awards. The rankings consist of sub-lists covering fundraising, investment, portfolio management, and exit pioneers, sector-specific investment pioneers, and ESG pioneers — designed to identify pioneering investment institutions that accurately captured industry trends in the new cycle, maintained high-frequency and high-precision investment performance, provided long-term support to help portfolio companies break through market challenges, precisely timed exits, and delivered substantial returns.
Qiming Venture Partners received:
- Top 20 Investment Pioneers of the Year
- Top 10 Exit Pioneers of the Year
- Top 20 Portfolio Management Pioneers of the Year
- Top 20 Embodied AI/Robotics Investment Pioneers of the Year
- Top 20 Healthcare Investment Pioneers of the Year
- Top 5 ESG Pioneers of the Year
TMTpost noted that investment institutions continued the explosive deal-making growth seen in H1 2025, with overall investment stages shifting earlier. Compared to 2024, the combined deal count of the top 10 institutions on the AI Application and AI Hardware investment pioneer lists rose from 172 to 383 (a 223% increase), while total deal value climbed from 7.4 billion to 15.2 billion yuan (a 205% increase). The data tells its own story — China's venture capital market, supercharged by the AI wave, has undeniably entered a recovery trajectory, and has arguably posted its hottest performance in nearly three years.
Source | TMTpost
Past Highlights
Qiming Perspectives | William Hu: Chinese Innovation Is Moving from Isolated Breakthroughs to Large-Scale, Comprehensive Advances Qiming Honors | Five Qiming Venture Partners Investors Named to ChinaVenture 2025 Investor Rankings Qiming Honors | Five Qiming Venture Partners Investors Named to Forbes China 2025 Midas List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, with more than 210 listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), GenScript ProBio (688520.SH), Insilico Medicine (03696.HK), Arbutus Biopharma, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.